Impact of host cell variation on the neutralization of HIV-1 in vitro

Victoria R. Polonis, Hanneke Schuitemaker, Evelien M. Bunnik, Bruce K. Brown, Gabriella Scarlatti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: In this review we present current advances in our understanding of HIV-1 neutralization assays that employ primary cell types, as compared with those that utilize cell lines and the newer, more standardized pseudovirus assays. A commentary on the challenges of standardizing in-vitro neutralization assays using primary cells is included. RECENT FINDINGS: The data from reporter cell line neutralization assays may agree with results observed in primary cells; however, exceptions have recently been reported. Multiple variables exist in primary cell assays using peripheral blood mononuclear cells from HIV-seronegative donors; in-vitro neutralization titers can vary significantly based on the donor cells used for assay targets and for virus propagation. Thus, more research is required to achieve validated primary cell neutralization assays. SUMMARY: HIV-vaccine-induced antibody performance in the current neutralization assays may function as a 'gatekeeper' for HIV-1 subunit vaccine advancement. Development of standardized platforms for reproducible measurement of in-vitro neutralization is therefore a high priority. Given the considerable variation in results obtained from some widely applied HIV neutralization platforms, parallel evaluation of new antibodies using different host cells for assay targets, as well as virus propagation, is recommended until immune correlates of protection are identified.

Original languageEnglish
Pages (from-to)400-407
Number of pages8
JournalCurrent Opinion in HIV and AIDS
Volume4
Issue number5
DOIs
Publication statusPublished - Sep 2009

Fingerprint

HIV-1
HIV
Viruses
Cell Line
AIDS Vaccines
Subunit Vaccines
Antibodies
In Vitro Techniques
Blood Cells
Research

Keywords

  • Assay standardization
  • HIV neutralization
  • Host cell
  • Humoral immunity
  • Vaccine assessment

ASJC Scopus subject areas

  • Hematology
  • Oncology(nursing)
  • Immunology
  • Infectious Diseases
  • Virology
  • Oncology

Cite this

Impact of host cell variation on the neutralization of HIV-1 in vitro. / Polonis, Victoria R.; Schuitemaker, Hanneke; Bunnik, Evelien M.; Brown, Bruce K.; Scarlatti, Gabriella.

In: Current Opinion in HIV and AIDS, Vol. 4, No. 5, 09.2009, p. 400-407.

Research output: Contribution to journalArticle

Polonis, Victoria R. ; Schuitemaker, Hanneke ; Bunnik, Evelien M. ; Brown, Bruce K. ; Scarlatti, Gabriella. / Impact of host cell variation on the neutralization of HIV-1 in vitro. In: Current Opinion in HIV and AIDS. 2009 ; Vol. 4, No. 5. pp. 400-407.
@article{9b06adc3ddbc44bcae5500ac1d281ca7,
title = "Impact of host cell variation on the neutralization of HIV-1 in vitro",
abstract = "PURPOSE OF REVIEW: In this review we present current advances in our understanding of HIV-1 neutralization assays that employ primary cell types, as compared with those that utilize cell lines and the newer, more standardized pseudovirus assays. A commentary on the challenges of standardizing in-vitro neutralization assays using primary cells is included. RECENT FINDINGS: The data from reporter cell line neutralization assays may agree with results observed in primary cells; however, exceptions have recently been reported. Multiple variables exist in primary cell assays using peripheral blood mononuclear cells from HIV-seronegative donors; in-vitro neutralization titers can vary significantly based on the donor cells used for assay targets and for virus propagation. Thus, more research is required to achieve validated primary cell neutralization assays. SUMMARY: HIV-vaccine-induced antibody performance in the current neutralization assays may function as a 'gatekeeper' for HIV-1 subunit vaccine advancement. Development of standardized platforms for reproducible measurement of in-vitro neutralization is therefore a high priority. Given the considerable variation in results obtained from some widely applied HIV neutralization platforms, parallel evaluation of new antibodies using different host cells for assay targets, as well as virus propagation, is recommended until immune correlates of protection are identified.",
keywords = "Assay standardization, HIV neutralization, Host cell, Humoral immunity, Vaccine assessment",
author = "Polonis, {Victoria R.} and Hanneke Schuitemaker and Bunnik, {Evelien M.} and Brown, {Bruce K.} and Gabriella Scarlatti",
year = "2009",
month = "9",
doi = "10.1097/COH.0b013e32832edc50",
language = "English",
volume = "4",
pages = "400--407",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Impact of host cell variation on the neutralization of HIV-1 in vitro

AU - Polonis, Victoria R.

AU - Schuitemaker, Hanneke

AU - Bunnik, Evelien M.

AU - Brown, Bruce K.

AU - Scarlatti, Gabriella

PY - 2009/9

Y1 - 2009/9

N2 - PURPOSE OF REVIEW: In this review we present current advances in our understanding of HIV-1 neutralization assays that employ primary cell types, as compared with those that utilize cell lines and the newer, more standardized pseudovirus assays. A commentary on the challenges of standardizing in-vitro neutralization assays using primary cells is included. RECENT FINDINGS: The data from reporter cell line neutralization assays may agree with results observed in primary cells; however, exceptions have recently been reported. Multiple variables exist in primary cell assays using peripheral blood mononuclear cells from HIV-seronegative donors; in-vitro neutralization titers can vary significantly based on the donor cells used for assay targets and for virus propagation. Thus, more research is required to achieve validated primary cell neutralization assays. SUMMARY: HIV-vaccine-induced antibody performance in the current neutralization assays may function as a 'gatekeeper' for HIV-1 subunit vaccine advancement. Development of standardized platforms for reproducible measurement of in-vitro neutralization is therefore a high priority. Given the considerable variation in results obtained from some widely applied HIV neutralization platforms, parallel evaluation of new antibodies using different host cells for assay targets, as well as virus propagation, is recommended until immune correlates of protection are identified.

AB - PURPOSE OF REVIEW: In this review we present current advances in our understanding of HIV-1 neutralization assays that employ primary cell types, as compared with those that utilize cell lines and the newer, more standardized pseudovirus assays. A commentary on the challenges of standardizing in-vitro neutralization assays using primary cells is included. RECENT FINDINGS: The data from reporter cell line neutralization assays may agree with results observed in primary cells; however, exceptions have recently been reported. Multiple variables exist in primary cell assays using peripheral blood mononuclear cells from HIV-seronegative donors; in-vitro neutralization titers can vary significantly based on the donor cells used for assay targets and for virus propagation. Thus, more research is required to achieve validated primary cell neutralization assays. SUMMARY: HIV-vaccine-induced antibody performance in the current neutralization assays may function as a 'gatekeeper' for HIV-1 subunit vaccine advancement. Development of standardized platforms for reproducible measurement of in-vitro neutralization is therefore a high priority. Given the considerable variation in results obtained from some widely applied HIV neutralization platforms, parallel evaluation of new antibodies using different host cells for assay targets, as well as virus propagation, is recommended until immune correlates of protection are identified.

KW - Assay standardization

KW - HIV neutralization

KW - Host cell

KW - Humoral immunity

KW - Vaccine assessment

UR - http://www.scopus.com/inward/record.url?scp=69549114400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549114400&partnerID=8YFLogxK

U2 - 10.1097/COH.0b013e32832edc50

DO - 10.1097/COH.0b013e32832edc50

M3 - Article

C2 - 20048704

AN - SCOPUS:69549114400

VL - 4

SP - 400

EP - 407

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 5

ER -